Latest / Bloomberg Intelligence
Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.
See omnystudio.com/listener for privacy information.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.